Aerie Pharmaceuticals (NSDQ:AERI) said today that Nasdaq has halted trading of the company’s common stock as an FDA committee convenes to review Aerie’s new drug application for its Rhopressa glaucoma and ocular hypertension drug.
The Irvine, Calif.-based company submitted the NDA in February and the FDA is slated to finishing reviewing the application by Feb. 28, 2018.
Get the full story at our sister site, Drug Delivery Business News.
The post Nasdaq halts trading of Aerie stock as FDA reviews Rhopressa NDA appeared first on MassDevice.